Phathom Pharmaceuticals Faces Legal Challenge Over VOQUEZNA Exclusivity

MT Newswires Live10-23

Phathom Pharmaceuticals (PHAT) said Friday that BDR Pharmaceuticals International has sued the US Food and Drug Administration, or FDA, challenging its alleged refusal to accept a generic drug application referencing Phathom's VOQUEZNA.

BDR alleges the FDA improperly applied the GAIN Act to extend the drug's new chemical entity exclusivity, it said.

Phathom said the FDA correctly granted its citizen petition in June 2025, recognizing exclusivity for VOQUEZNA tablets through May 3, 2032.

The company said it is evaluating the lawsuit and intends to take appropriate action to protect its exclusivity rights.

Phathom Pharmaceuticals was down 2.9% in Friday premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment